News summaryEast MoneyOct 30, 2026, 12:00 AM
Eli Lilly Beats Q3 Revenue and Adjusted EPS Expectations
Eli Lilly reported third-quarter revenue of $24.397 billion, up 39% year over year and above the analyst average forecast of $22.61 billion. [[fact:fact-5yddqwl5h]] The company reported adjusted earnings per share of $7.48, above expectations of $6.26. [[fact:fact-q10vd54uh]] Mounjaro global third-quarter sales rose 65% year over year to $10.723 billion. [[fact:fact-h7okpic4j]] Zepbound third-quarter sales were $5.352 billion, up 49% year over year. [[fact:fact-etwbp92xe]] Foundayo third-quarter sales were $184 million, below analysts’ approximately $229 million expectation. [[fact:fact-p6jjn7eel]]